RightCare Solutions believes that evidence-based technology can empower nurses, discharge planners, and case managers to revolutionize the discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day readmissions exact on the healthcare system. Based
on a decade of research conducted at the University of Pennsylvania School of Nursing, the D2S2 platform enables continuous point-of-care decision support, optimizes workflow, and dramatically improves post-acute care transitions.
Eric Heil is the Board Observer at Adynxx Inc.
Mr. Heil joined Domain in 2008, and became an Entrepreneur-In-Residence in 2012.
In 2011, while at Domain, Mr. Heil co-founded RightCare Solutions, Inc., a Domain healthcare IT portfolio company.
After successfully closing its Series A financing in October 2012, Mr. Heil became President & CEO of RightCare Solutions, Inc.
From 2008-2012, Mr. Heil assisted with the review of new investment opportunities and helped existing Domain portfolio companies with financing strategies and would take an active role in business development processes.
In particular, Mr. Heil was involved in Domain’s public equity investment in Achillion Pharmaceuticals and private investments in Adynxx and Afferent Pharmaceuticals.
In 2009 and early 2010, Mr. Heil served as Director of Business Development for Corthera, a Domain portfolio company, which was acquired by Novartis in February 2010.
Improving patient and caregiver outcomes and quality of life through the use of technology, novel drug treatments, and therapeutics has been the driving force throughout my professional career. I have always been motivated to look beyond the current solutions to identify new and novel approaches. When I first learned about the D2S2 Care Transitions Software Platform and recognized how truly cutting edge it was, I immediately wanted to be a part of the RightCare team.
Throughout my career, I have had the distinct pleasure of working with some of the best and brightest individuals in the business who also share my passion for improving overall quality of life. I have learned a great deal from these collaborative relationships and look forward to many years of continued growth.
My family is and always has been the most important aspect of my life. As my two children go through teen and pre-teen life experiences, I realize the gift that they are and how quickly this time goes.
My life’s mission is to build revolutionary IT products, solutions, and services. Coming from a family of doctors, I was acutely aware of the lack of IT adoption in healthcare delivery and the drag it is on the nation’s physical and economic health. For the past decade, I have focused my energies building solutions to help improve quality of care and reduce waste in the healthcare system. The challenges are enormous, but I have complete faith in our collective ability to turn things around with innovation and ingenuity. In that quest, I intend to help RightCare bring evidence-based decision support and care transition tools to market.
Prior to RightCare, I was a Principal and VP of Technology at Audacious Inquiry (AI), a healthcare IT and management consulting business.
Eckard Weber is the Board Director at Adynxx Inc.
Dr. Weber joined Domain in 2001 as a Partner where he specializes in creating companies around promising new pharmaceutical products.
He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including,
Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Antibacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals.
He currently serves as interim CEO of Sonexa Therapeutics.
He is Chairman of the Board at, Ascenta Therapeutics, Ocera Therapeutics, Orexigen Therapeutics, Sequel Pharmaceuticals, Tobira Therapeutics.
Dr. Weber is an Observer on the Board of Syndax Pharmaceuticals.
A Board member of Adynxx.
Dennis Podlesak is the Board Chairman Adynxx Inc.
Dennis Podlesak is a Partner at Domain Associates LLC, an exclusively life science focused venture capital firm.
Since joining the Domain team, Dennis has served as an active investor and a founder of a number of Domain companies, and also as a Chief Executive Officer or Executive Chairman for a number of Domains promising growth companies.
Dennis first served as the Chief Executive Officer of Peninsula Pharmaceuticals and after building the company, led the sale of Peninsula to Johnson & Johnson.
In his next role, Dennis was a founder and the Chief Executive Officer of Cerexa, and led the sale of Cerexa to Forest Laboratories.
In his next role, Dennis was again a founder and the Chief Executive Officer of Calixa Therapeutics and successfully led the growth and sale of Calixa to Cubist Pharmaceuticals.
Richard Perlman is the President of Compass Partners, L.L.C. (Compass Partners), a merchant banking and financial advisory firm he founded in 1995 that specializes in middle market companies and corporate restructuring. He served as Chairman and Director of TurboChef Technologies, Inc. from October 2003 until January 2009, when TurboChef was acquired by The Middleby Corporation. He was the Chairman of PracticeWorks, Inc. from March 2001 until its acquisition by The Eastman Kodak Company in October 2003. Richard served as Chairman and Treasurer of AMICAS, Inc. (formerly VitalWorks Inc.) from January 1998 and as a Director from March 1997 until the completion of the spin-off of PracticeWorks, Inc. in March 2001.
Prior to this time, Richard was involved in the acquisition and operation of several private companies in the home furnishings, automobile replacement parts and real estate industries where he was a principal and Chief Executive Officer.
He was a Director of Alloy, Inc.
Passion, energy, and curiosity have driven me throughout my career in healthcare, which has culminated in becoming a member of RightCares founding team and its chief commercial officer. Im honored to be a part of such a high-quality team and thrilled to have the opportunity to bring Kathys years of research to life. People often ask me why I have chosen to spend my life in healthcare, and my answer is usually the following: This industry focuses on improving peoples lives, yet is the highest-cost, highest-growth, and most screwed up sector in our countrys entire economy. Why would I want to do anything else?
When Im not focusing on helping case managers, discharge planners, and nurses get the best possible outcomes for their patients, I go on tough bike rides with my wife, I (attempt to) cook delicious new recipes, and I fret about the state of Philadelphia sports teams.